PRRX1 and breast carcinoma: These data are consistent with other in vitro studies in breast cancer cell lines in which silencing of both Twist1 and PRRX1, another EMT‐TF, was required for efficient metastatic outgrowth at distant sites (Ocaña et al., 2012).